Results 21 to 30 of about 10,873 (203)

Ac-SDKP and eplerenone confer additive cardioprotection against angiotensin II-induced cardiac injury in C57BL/6J mice

Journal of Molecular and Cellular Cardiology Plus
Eplerenone, a mineralocorticoid receptor antagonist, is an anti-hypertensive and cardioprotective drug. We showed that N-Acetyl-Seryl-Aspartyl-Proline (Ac-SDKP) exerts beneficial effects on the heart.
Suhail Hamid, Sarah Sarkar, Hongmei Peng, Khalid Matrougui, Pablo A. Ortiz, Jiang Xu, Tang-Dong Liao, Robert A. Knight, Nour-Eddine Rhaleb   +8 more
doaj   +2 more sources

Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece

ClinicoEconomics and Outcomes Research, 2016
Kostas Athanasakis,1 Aikaterini Bilitou,2 Dawn Lee,3 Eleftheria Karampli,1 Apostolos Karavidas,4 John Parissis,5 Georgia Sykara,2 John Kyriopoulos1 1Department of Health Economics, National School of Public Health, Athens, Greece; 2Pfizer Hellas, Athens,
Athanasakis K, Bilitou A, Lee D, Karampli E, Karavidas A, Parissis J, Sykara G, Kyriopoulos J   +7 more
doaj   +1 more source

Chemical stability study of diuretics in a concomitant simple suspension with magnesium oxide [PDF]

Journal of Pharmaceutical Health Care and Sciences
Background A simple suspension method has been widely used in Japan, however, chemical interactions among drugs in co-suspensions have not been fully clarified.
Ginjiro Kato, Hidemichi Mitome, Mayu Terada, Noriaki Hidaka, Mamoru Tanaka, Kazuki Akira   +5 more
doaj   +2 more sources

Comparative Efficacy of Aldosterone-Related Sodium-Retention Pathway Therapies for Resistant Hypertension: A Drug-Level Network Meta-Analysis of Randomized Controlled Trials. [PDF]

J Clin Hypertens (Greenwich)
ABSTRACT Mineralocorticoid receptor antagonists (MRAs), aldosterone synthase inhibitors (ASIs), and epithelial sodium channel (ENaC) blockade target different levels of the aldosterone‐related sodium‐retention pathway in resistant hypertension (RH), but the comparative efficacy of individual agents remains uncertain.
Tsou YL, Wang YH, Lin YS, Chen CL.
europepmc   +2 more sources

Chinese Expert Consensus on the Clinical Application of Finerenone in Geriatric Comorbidities: Geriatrics Branch of Chinese Medical Association, Cardiovascular Group of Geriatrics Branch of Chinese Medical Association. [PDF]

Aging Med (Milton)
Mineralocorticoid receptor (MR) overactivation drives inflammation, oxidative stress, and fibrosis in the heart, kidneys, and vasculature, leading to cardiorenal dysfunction. MR signaling promotes hypertrophy, remodeling, and injury through pathways like oxidative stress and inflammation, resulting in vascular stiffness and progressive organ damage ...
Wang X, Zhang C.
europepmc   +2 more sources

Bilateral bullous central serous chorioretinopathy treated with PDT and eplerenone

American Journal of Ophthalmology Case Reports, 2022
Purpose: To report a case evaluating PDT and eplerenone therapy in a patient with bilateral bullous central serous chorioretinopathy. Observations: A 30-year-old male was referred for worsening bilateral bullous central serous chorioretinopathy (bCSCR ...
William J. Anderson, Bradley T. Smith
doaj   +1 more source

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy

Scientific Reports, 2022
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto, Rossella D’Aloisio, Chiara De Nicola, Federica Evangelista, Maria Ludovica Ruggeri, Luca Cerino, Maria Beatrice Simonelli, Agbéanda Aharrh-Gnama, Marta Di Nicola, Annamaria Porreca, Rodolfo Mastropasqua   +10 more
doaj   +1 more source

Eplerenone for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2011
Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction.
Tina Sc, Tam, May Hy, Wu, Sarah C, Masson, Matthew P, Tsang, Sarah N, Stabler, Angus, Kinkade, Anthony, Tung, Aaron M, Tejani   +7 more
openaire   +2 more sources

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus

Бюллетень сибирской медицины, 2021
Aim. To study the effect of eplerenone on the activity of free radical oxidation and renal function in rats with experimental diabetes mellitus induced by streptozotocin.Materials and methods. Experiments were carried out on 36 male Wistar rats. Diabetes
A. Yu. Zharikov, S. O. Filinova, O. N. Mazko, O. G. Makarova, I. P. Bobrov, V. M. Bryukhanov   +5 more
doaj   +1 more source

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

Лечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova, R. I. Stryuk, V. V. Evdokimov, A. K. Kaptaeva   +3 more
doaj   +1 more source